Investors

Press Releases

All Releases

View Summary Regeneron's Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
Nov 25, 2013
PDF 12.0 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Nov 22, 2013
PDF 18.2 KB Add to Briefcase
View Summary Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Nov 22, 2013
PDF 18.8 KB Add to Briefcase
View Summary Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
Nov 12, 2013
PDF 21.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema
Nov 7, 2013
PDF 22.1 KB Add to Briefcase
View Summary Regeneron Reports Third Quarter 2013 Financial and Operating Results
Nov 5, 2013
PDF 36.2 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Nov 1, 2013
PDF 11.5 KB Add to Briefcase
View Summary Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Oct 24, 2013
PDF 10.7 KB Add to Briefcase
View Summary Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion
Oct 21, 2013
PDF 18.3 KB Add to Briefcase
View Summary Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Oct 16, 2013
PDF 19.6 KB Add to Briefcase
View Summary Regeneron to Report Third Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2013
Oct 10, 2013
PDF 9.3 KB Add to Briefcase
View Summary Regeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting
Sep 17, 2013
PDF 17.3 KB Add to Briefcase
View Summary Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Sep 10, 2013
PDF 10.2 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Aug 29, 2013
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Aug 27, 2013
PDF 9.3 KB Add to Briefcase
View Summary Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice
Aug 7, 2013
PDF 10.5 KB Add to Briefcase
View Summary Regeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema
Aug 6, 2013
PDF 22.2 KB Add to Briefcase
View Summary Regeneron Reports Second Quarter 2013 Financial and Operating Results
Aug 6, 2013
PDF 33.6 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Jul 26, 2013
PDF 18.6 KB Add to Briefcase
View Summary Regeneron to Report Second Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2013
Jul 2, 2013
PDF 9.4 KB Add to Briefcase
Showing 21-40 of 215 Page: 1 2 3 4 5 6 ... 11  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)